Diabetes Mellitus, Postmenopausal osteoporosis
Conditions
Brief summary
Changes in muscle mass and muscle strength from baseline to month 12., Changes in insulin sensitivity (Hb1Ac, HOMA-IR, fasting glucose, oral glucose tolerance test (OGTT)) from baseline to month 12.
Detailed description
Changes in DPP-4 and GLP-1 from baseline to month 12., Changes in carboxy-terminal collagen crosslinks (CTX) and procollagen type I N-terminal propeptide (PINP) from baseline to month 12., Change in lumbar spine BMD from baseline to month 12., Change in advanced glycation end products (AGEs) from baseline to month 12., Changes in muscle strength from baseline to month 1 and 3., Changes in insulin sensitivity (Hb1Ac, HOMA-IR, and fasting glucose) from baseline to month 1 and 3
Interventions
DRUGDENOSUMAB
DRUGSALINE
Sponsors
Region Midtjylland
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in muscle mass and muscle strength from baseline to month 12., Changes in insulin sensitivity (Hb1Ac, HOMA-IR, fasting glucose, oral glucose tolerance test (OGTT)) from baseline to month 12. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in DPP-4 and GLP-1 from baseline to month 12., Changes in carboxy-terminal collagen crosslinks (CTX) and procollagen type I N-terminal propeptide (PINP) from baseline to month 12., Change in lumbar spine BMD from baseline to month 12., Change in advanced glycation end products (AGEs) from baseline to month 12., Changes in muscle strength from baseline to month 1 and 3., Changes in insulin sensitivity (Hb1Ac, HOMA-IR, and fasting glucose) from baseline to month 1 and 3 | — |
Countries
Denmark
Outcome results
None listed